ABBV Dec 2025 105.000 call
| Previous Close | 71.57 |
| Open | 71.57 |
| Bid | 60.55 |
| Ask | 62.10 |
| Strike | 105.00 |
| Expire Date | 2025-12-19 |
| Day's Range | 71.57 - 71.57 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 14 |
CNW GroupQULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent both episodic and chronic migraine.
Barrons.comTeva Earnings Are Soon. What Could Keep the Stock Gains Going.
Shares of Teva Pharmaceutical Industries have done something unusual this year: They’ve gone up. The company’s American depositary receipt, which spent much of the past decade falling in value or stagnating at rock-bottom levels, has shot up nearly 35% this year. On Wednesday morning, executives will present the Teva’s first-quarter results, and face questions from Wall Street about whether the company can sustain this upswing.
Insider Monkey15 Best S&P 500 Dividend Stocks To Buy Now
In this article, we discuss 15 best S&P 500 dividend stocks to buy now. You can skip our detailed analysis of dividend stocks in the S&P 500 and their past performance, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy Now. It’s been a dynamic first quarter for the stock market. […]
